Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
Our Experts

Frank Sciurba, M.D.

Pittsburgh Pulmonologists Studying Drug for Chronic Obstructive Pulmonary Disease Patients

PITTSBURGH, March 19, 2001 — Pulmonologists from the University of Pittsburgh Division of pulmonary, allergy and critical care medicine are studying an experimental drug that could make breathing easier for people with chronic obstructive pulmonary disease (COPD).

COPD is a progressive illness that leads to the obstruction of air into and out of the lungs and shortness of breath. It includes chronic bronchitis, emphysema and asthmatic bronchitis; 90 percent of COPD is due to smoking. It is the fourth leading causes of death in the United States.

The international study will evaluate whether Spiriva (Tiotropium), a bronchodilator that opens the airway passages to make it easier for air to get in and out of the lungs, taken by inhalation once per day, can decrease the sensation of shortness of breath during exercise resulting in improvement in the length of time that a person can exercise.

“A study presented last year by researchers at the World Congress on Lung Health and the 10th European Respiratory Society (ERS) Annual Congress showed that Spiriva was effective in improving key clinical and health outcomes in COPD patients,” said Frank Sciurba, M.D., associate professor of medicine at the University of Pittsburgh and principal investigator in the study. “The drug is similar to Atrovent™, which is a widely used bronchodilator. One of the main differences between the two drugs is that Spiriva can open up the airways for a longer period than Atrovent, which may allow patients to take fewer doses per day."

Up to 160 patients with COPD will be included in the study, which will take place in the United States, Canada and Australia. Approximately 16 to 24 patients between the ages of 40 and 70 will participate in Pittsburgh. Half of the patients in the randomized double blind study will receive inhaled Spiriva for six weeks, while half will receive an inhaled placebo (inactive) medication. All patients must have a diagnosis of COPD, have a cigarette smoking history of 10 pack-years and must not require supplemental oxygen treatment.

The study is sponsored by Boehringer Ingelheim Pharmaceuticals Inc. of Ingelheim, Germany. Participants will be reimbursed $675 for their time upon completion of the study.

For more information on the study, call 412-692-2800.

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

Pittsburgh, PA, USA |